Melanoma Metastasized to the Brain and Steroids

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-06

Study Completion Date

2028-06-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial is to clarify whether treatment with a checkpoint inhibitor alone (pembrolizumab) or two in combination (ipilimumab and nivolumab), results in clinical benefit for MM patients with brain metastases and in need of steroid treatment. Patients will be treated in four arms depending on steroid dose level at inclusion (\> 10 \< 25 mg prednisolone or \> 25 mg prednisolone) and treatment (pembrolizumab alone or the combination of ipilimumab and nivolumab).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

NCT00623766

Melanoma

COMPLETED PHASE2

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

NCT03873818

Clinical Stage IV Cutaneous Melanoma AJCC v8 Metastatic Malignant Neoplasm in the Brain Metastatic Melanoma +1 more

COMPLETED PHASE2

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

NCT04899921

Melanoma Metastatic Melanoma

TERMINATED PHASE2

Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases

NCT02374242

Melanoma Brain Metastases

ACTIVE_NOT_RECRUITING PHASE2

Biomarkers in Immunotherapy of Melanoma

NCT05878977

Metastatic Melanoma Immune Checkpoints Inhibitors Gastrointestinal Microbiome (Bacterial and Viral) +1 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cancer immunotherapy with checkpoint inhibitors (CPI) has demonstrated significant response rates, with clinical responses of exceptional duration observed in pivotal clinical trials for multiple types of solid tumors. Results from clinical trials demonstrate a considerable survival benefit of CPI over standard treatments, leading to registration of CPI for lung-, head and neck-, bladder-, renal cancer, lymphomas and metastatic melanoma (MM). To date, CPI appear to hold the key for longterm survival - at least for patients treated in clinical trials.

Patients enrolled in pivotal clinical trials for immunotherapy of MM are highly selected and does not include patients with brain metastases. Small phase II studies lend support to CPI to yield responses in melanoma that has metastasized to the brain. However, a large proportion of patients that develop brain metastasis will require continued systemic treatment with steroids to alleviate symptoms from the central nervous system (CNS). This group of patients are not offered treatment with CPI, as it is generally assumed that steroid treatment hamper their clinical efficacy. Thus, this group of patients face a large unmet need.

Due to the immune inhibiting effects, steroids are used to manage immune-related adverse events (irAEs) induced by CPI treatment. However, patients receiving steroids in this context are still able to achieve and maintain clinical benefit even after stopping treatment.

It is not known whether steroid treatment at the time of initiation of CPI treatment diminishes the treatment effect, as patients in need of steroid treatment are generally excluded from clinical trials.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Six patients are enrolled in each arm. If clinical benefit is observed, each arm will be expanded to enroll a total of 20 patients.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Intervention Type DRUG

In combination with trametinib

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed metastatic melanoma with radiologically verified brain metastasis
* Need for systemic steroid treatment (prednisolone \> 10 mg daily; dexamethasone \> 1.6 mg daily, hydrocortisone \> 40 mg daily or equivalent) due to brain metastasis
* At least one measurable lesion according to RECIST version 1.1 guidelines
* Evaluable intracranial disease
* 18 years of age or older
* Performance status 0-2
* Able to undergo MRI with gadolinium contrast agent
* Adequate hematological and organ function
* No significant toxicity from previous cancer treatments (CTC\<1)
* Women of childbearing potential: Negative serum pregnancy test and must use effective contraception. This applies from screening and until 6 months after treatment. Birth control pills, spiral, depot injection with gestagen, subdermal implantation, hormonal vaginal ring and transdermal depot patch are all considered effective contraceptives
* Men with female partner of childbearing potential must use effective contraception from screening and until 6 months after treatment. Effective contraceptives are as described above for the female partner. In addition documented vasectomy and sterility or double barrier contraception are considered effective contraceptives
* Signed statement of consent after receiving oral and written study information.
* Willingness to participate in the planned treatment and follow-up and capable of handling toxicities.
* For arm E specifically: Tumor cells must harbor BRAF mutation.

Exclusion Criteria

* Another malignancy or concurrent malignancy unless disease-free for 3 years
* Ocular melanoma
* Neurological symptoms from brain metastases present at baseline despite steroid treatment, unless symptoms are related to prior surgery
* Known hypersensitivity to one of the active drugs or excipients
* Acute or chronic infections with HIV or hepatitis
* Any medical condition that will interfere with patient compliance or safety
* Prior treatment with anti-PD-1/PD-L1/PD-L2/CTLA-4 antibodies in the metastatic setting
* Prior systemic treatment with anti-PD-1/PD-L1/PD-L2/CTLA-4 antibodies in the adjuvant setting, unless completed more than 6 months before enrolment in this study
* Simultaneous treatment with other experimental drugs or other anti-cancer drugs
* Pregnant or breastfeeding females.
* For arm E specifically: Prior treatment with BRAF/MEK inhibitors.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No